Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis

Leukemia Research

Volumn 36, Issue 11, 2012, Pages 1330-1333

  Cornet, Edouard ^a,b   Dumézy, Florent ^a   Roumier, Christophe ^a,b   Lepelley, Pascale ^a,b   Jouy, Nathalie ^c   Philippe, Nathalie ^a   Renneville, Aline ^a   Berthon, Céline ^a   Nelken, Brigitte ^a   Quesnel, Bruno ^b   Preudhomme, Claude ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

^c IFR114 IRCL   (France)

Author keywords

Acute myeloid leukaemia; Core binding factor; KIT mutation; Leukaemic intiating cell; Minimal residual disease; Systemic mastocytosis

Indexed keywords

ANTINEOPLASTIC AGENT; CORE BINDING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AML1 ETO GENE; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CBF BETA MYH11 GENE; CHROMOSOME 16; CHROMOSOME INVERSION; CHROMOSOME INVERSION 16; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONSOLIDATION CHEMOTHERAPY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LEUKEMIA ASSOCIATED ABERRANT IMMUNOPHENOTYPE; MALE; MAST CELL; MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW CYTOMETRY; ONCOGENE C KIT; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION; SYSTEMIC MASTOCYTOSIS;

ADOLESCENT; CELL LINEAGE; CORE BINDING FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MASTOCYTOSIS; MIDDLE AGED; MUTATION; NEOPLASTIC STEM CELLS; STEM CELL FACTOR;

EID: 84866327664     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.001     Document Type: Article

References (16)

1. Valent P., Akin C., Escribano L., Födinger M., Hartmann K., Brockow K., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
2. Pardanani A., Kimlinger T., Reeder T., Li C., Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004, 28:777-783.
3. Escribano L., Orfao A., Díaz-Agustin B., Villarrubia J., Cerveró C., López A., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998, 91:2731-2736.
4. Sotlar K., Horny H., Simonitsch I., Krokowski M., Aichberger K.J., Mayerhofer M., et al. Cd25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (sm) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28:1319-1325.
5. Pullarkat V., Bedell V., Kim Y., Bhatia R., Nakamura R., Forman S., et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007, 31:261-265.
6. Kern W., Schoch C., Haferlach T., Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005, 56:283-309.
7. Boissel N., Leroy H., Brethon B., Philippe N., de Botton S., Auvrignon A., et al. Incidence and prognostic impact of c-kit, flt3, and ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20:965-970.
8. Leroy H., de Botton S., Grardel-Duflos N., Darre S., Leleu X., Roumier C., et al. Prognostic value of real-time quantitative pcr (rq-pcr) in aml with t(8;21). Leukemia 2005, 19:367-372.
9. Olaru D., Campos L., Flandrin P., Nadal N., Duval A., Chautard S., et al. Multiparametric analysis of normal and postchemotherapy bone marrow: implication for the detection of leukemia-associated immunophenotypes. Cytometry B Clin Cytom 2008, 74:17-24.
10. Krauter J., Gorlich K., Ottmann O., Lubbert M., Dohner H., Heit W., et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003, 21:4413-4422.
11. Sotlar K., Marafioti T., Griesser H., Theil J., Aepinus C., Jaussi R., et al. Detection of c-kit mutation asp 816 to val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000, 53:188-193.
12. Akin C., Kirshenbaum A.S., Semere T., Worobec A.S., Scott L.M., Metcalfe D.D. Analysis of the surface expression of c-kit and occurrence of the c-kit asp816val activating mutation in t cells, b cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000, 28:140-147.
13. Bernd H., Sotlar K., Lorenzen J., Osieka R., Fabry U., Valent P., et al. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. report of an unusual case and review of the literature. J Clin Pathol 2004, 57:324-328.
14. Nagai S., Ichikawa M., Takahashi T., Sato H., Yokota H., Oshima K., et al. The origin of neoplastic mast cells in systemic mastocytosis with aml1/eto-positive acute myeloid leukemia. Exp Hematol 2007, 35:1747-1752.
15. Sperr W.R., Drach J., Hauswirth A.W., Ackermann J., Mitterbauer M., Mitterbauer G., et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 2005, 11:6787-6792.
16. Nerlov C. C/ebpalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004, 4:394-400.